Aggressive Non-Hodgkin's Lymphoma: Types and Treatments
Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve the B-cells or T-cells of the immune system and often present as tumors in the lymph nodes. These high-grade cancers will move into the advanced stages much faster than indolent, low-grade tumors.
Aggressive NHLs usually respond to treatment, including chemotherapy, radiation, immunotherapy and radioimmunotherapy regimens.
The Zevalin radioimmunotherapy regimen is now approved for treatment of certain follicular lymphomas
Patients who are looking for more advanced treatment or who have lymphoma that does not respond to standard treatment may want to consider a clinical study. Click here to find clinical trials in your area.
The following are Aggressive Non-Hodgkin’s lymphomas:
- Large noncleaved cell lymphomas
- Small noncleaved cell lymphomas
- Blastic NK-cell lymphoma
- Large cell immunoblastic lymphoma
- Angioimmunoblastic lymphoma
- Diffuse mixed cell lymphoma
- Diffuse large cell lymphoma
- Burkitt’s lymphoma
- Peripheral T-cell lymphoma
- Lymphoblastic lymphoma
- Anaplastic large cell lymphoma
- Adult T-cell leukemia/lymphoma
- Mantle-cell lymphoma
Non-Hodgkin's Lymphoma Information Pages:
- Non-Hodgkin's Lymphomas
- Non-Hodgkin's Lymphoma: Diagnosis
- Non-Hodgkin's Lymphoma: Aggressive Lymphomas
- Non-Hodgkin's Lymphoma: Indolent Lymphomas
- Non-Hodgkin's Lymphoma: Treatment
- Non-Hodgkin's Lymphoma: Resources
Information on Childhood Lymphomas:
Photo: Pixabay
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
